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The Rta homolog encoded by murine gammaherpesvirus 68 (gHV68) gene 50 is essential for virus replication and is capable of driving
virus reactivation from the S11 latently infected B lymphoma cell line. Here we characterize Rta activation of gHV68 gene 57, which is
abundantly transcribed during the early phase of virus replication. Infection of murine fibroblasts with an Rta null virus demonstrated that
transcription of gene 57 is dependent on Rta expression. Analysis of the gene 57 promoter identified 2 distinct regions that are Rta
responsive, either in the context of the gene 57 promoter or when cloned upstream of a heterologous promoter. Sequence analysis of these
regions revealed homology to known Rta-responsive cis-elements in the closely related Kaposi’s sarcoma-associated viral (KSHV) genome.
In addition, two candidate binding sites for the cellular transcription factor RBP-Jn/CBF1 were also identified in one of the Rta-responsive
regions, which may play a role in mediating Rta transactivation similar to that observed in some KSHV Rta-responsive genes. Overall,
analysis of the gHV68 gene 57 promoter suggests that mechanisms of Rta activation are conserved among g2-herpesviruses.
D 2005 Elsevier Inc. All rights reserved.
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Murine gammaherpesvirus 68 (gHV68; also referred to as
MHV-68) is a natural pathogen of bank voles and field mice
(Blasdell et al., 2003; Blaskovic et al., 1980), and can infect
different strains of laboratory mice (Blaskovic et al., 1984;
Ehtisham et al., 1993; Mistrikova and Blaskovic, 1985;
Rajcani et al., 1985; Sunil-Chandra et al., 1992a, 1992b;
Svobodova et al., 1982). Similar to other g-herpesviruses,
gHV68 can establish two different types of infection, lytic
and latent. Acute virus replication can be detected in the
spleen, liver, lung, kidney, adrenal gland, heart, and thymus
(Blaskovic et al., 1984; Rajcani et al., 1985). gHV68 can
establish a latent infection in the spleen, peritoneal cells, and
lymph nodes (Cardin et al., 1996; Sunil-Chandra et al.,
1992a; Weck et al., 1999b), with B cells, macrophages, and0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.12.021
* Corresponding author. Fax: +1 404 727 7768.
E-mail address: sspeck@rmy.emory.edu (S.H. Speck).splenic dendritic cells serving as latency sites (Flano et al.,
2000; Sunil-Chandra et al., 1992a; Weck et al., 1999a).
Significantly, gHV68 has been associated with lymphopro-
liferative disease, lymphoma, and large-vessel arteritis in
mice (Usherwood et al., 1996; Weck et al., 1997).
While acute gammaherpesvirus infection is readily
resolved, latent infection is maintained for the life of the
host and is associated with a number of malignancies,
especially in immunocompromised hosts (Rickinson and
Kieff, 2001). Reactivation from latency and persistent lytic
viral replication might be important for gammaherpesvirus
persistence and associated disease. EBV and KSHV can
replicate persistently at mucosal sites (Ablashi et al., 2002;
Rickinson and Kieff, 2001), and this is thought to be
important for virus spread between hosts. KSHV lytic
replication may also play a role in KSHV-associated
Kaposi’s sarcoma (KS), since lytic genes implicated in
tumor formation and viral lytic replication have been
detected in KS lesions (Jenner and Boshoff, 2002; Kirshner
et al., 1999; Sarid et al., 1998; Sun et al., 1999). gHV6805) 169–179
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fatal inflammation of the great elastic arteries, and treatment
with drugs that inhibit lytic virus replication has a curative
effect (Dal Canto et al., 2000; Weck et al., 1997). Addition-
ally, passive transfer of antibody to the lytic antigen RCA in
B cell-deficient mice that have established latency resulted in
a decreased frequency of latently infected cells in the spleen
(Gangappa et al., 2002). Moreover, inhibition of lytic
replication using cidofivir decreased the frequency of
latently infected cells, providing further evidence for the
role of lytic replication for maintenance of latency (Gang-
appa et al., 2002).
Gammaherpesvirus immediate-early genes have been
shown to be critical regulators of lytic replication (Feederle
et al., 2000; Goodwin et al., 2001; Gradoville et al., 2000;
Jia and Sun, 2003; Lukac et al., 1998; Pavlova et al., 2003;
Ragoczy et al., 1998; Sun et al., 1998; Takada and Ono,
1989; Wu et al., 2000, 2001b; Zalani et al., 1996).
Regulation of the expression of immediate-early genes
seems to be essential for regulation of lytic cycle entry. For
example, it has been shown for EBV that factors that can
serve as reactivation inducers trigger a signal transduction
cascade that results in activation of the promoter of the
immediate-early gene BZLF1 (reviewed in Speck et al.,
1997). In vivo, immediate-early genes may serve as targets
for the immune response. The EBV immediate-early gene
product Rta has epitopes that are recognized by EBV-
specific cytotoxic lymphocytes (Pepperl et al., 1998), and
Rta-specific antibodies are detected in patients with EBV-
associated nasopharyngeal carcinoma (NPC) (Feng et al.,
2000, 2001). Immediate-early genes are involved in a
number of processes during the lytic cycle, including
transcriptional activation of downstream viral genes,
replication, cell cycle control, and protection from apopto-
sis (Flemington, 2001; Mocarski and C.T. Courcelle, 2001;
Pari et al., 2001; Rickinson and Kieff, 2001; Roizman and
Knipe, 2001; Sarisky et al., 1996; Swenson et al., 1999;
Wu et al., 2001a; Zacny et al., 1998). Transcriptional
activation by immediate-early genes is critical for the
expression of the viral lytic genes that are required for lytic
replication and virion production. This notion is empha-
sized by the observation that mutants in Rta that act as
dominant-negative inhibitors of transcriptional activation
severely inhibit the lytic cycle (Lukac et al., 1999; Wu et
al., 2001b).
The gHV68 immediate-early encoded Rta is a conserved
gammaherpesvirus gene product with a confirmed signifi-
cance for the gHV68 lytic cycle (Pavlova et al., 2003; Sun
et al., 1998; Wu et al., 2000, 2001b). gHV68 Rta does not
have significant homology to any known cellular genes.
Furthermore, gHV68 Rta has a relatively low level of
sequence identity with that of KSHV (16.4%), EBV
(13.1%), and HVS (26.6%). However, it is encoded by a
positionally conserved open reading frame in the viral
genome (Virgin et al., 1997) which, in all the characterized
gammaherpesviruses, exhibits a conserved pattern of tran-script splicing (Liu et al., 2000; Lukac et al., 1998; Sun et
al., 1998; van Santen, 1993; Whitehouse et al., 1997).
Significantly, splicing of the gHV68 Rta transcript extends
the open reading frame to encode an additional 94 amino
acids, and this extended region has a higher level of
homology to amino-terminal domains of the KSHV, EBV,
and HVS Rta (Liu et al., 2000). Additionally, Rta has a
conserved function and is critical for initiation of the lytic
cycle (see above), can act as a transcriptional activator of
viral genes (see below), and has roles for viral replication
and cell cycle regulation (Fixman et al., 1995; Gwack et al.,
2002; Pari et al., 2001; Sarisky et al., 1996; Zacny et al.,
1998). The EBV Rta functional domains have been
characterized; the amino-terminus contains overlapping
domains involved in DNA binding and dimerization, while
the carboxy-terminus contains a transactivation domain
(Hardwick et al., 1992; Manet et al., 1991). Extensive
analyses of Rta in other model gammaherpesviruses have
not been done, but deletion of the carboxy-terminus of both
KSHV and gHV68 Rta creates truncated proteins that have
no activity on their own, but act as dominant-negative
repressors of Rta transactivation and lytic replication (Lukac
et al., 1999; Wu et al., 2001b). These data indicate that the
carboxy-terminus contains the transactivation domain and
that the truncated proteins can still be recruited to the
promoter through sequences located in the amino-terminus,
probably either through dimerization with full-length Rta or
through binding to other transcription factors.
Rta has been shown to transactivate many early and late
viral gene promoters, including ORF 57, K-bZIP, PAN,
thymidine-kinase, kaposin, BHRF1, BMRF1 (ORF59),
BALF2 (ORF6), and the DR promoter (Cox et al., 1990;
Gruffat et al., 1990; Hung and Liu, 1999; Kenney et al.,
1989; Lukac et al., 1998, 1999, Quinlivan et al., 1993). In
addition, Rta can act on its own promoter (Deng et al., 2000;
Liu and Speck, 2003; Ragoczy and Miller, 2001; Sakakibara
et al., 2001). Rta does not seem to be a promiscuous
transactivator and displays promoter selectivity, as evi-
denced by the observation that KSHV Rta cannot trans-
activate certain promoters, such as the DNA polymerase and
glycoprotein B promoters (Lukac et al., 1998, 1999).
Transactivation is achieved through both direct DNA bind-
ing to the promoter (Chevallier-Greco et al., 1989; Cox et al.,
1990; Gruffat and Sergeant, 1994; Gruffat et al., 1992; Lukac
et al., 2001; Song et al., 2001; Wang et al., 2001), through
binding to other transcription factors (Chen et al., 2000; Liu
et al., 1996; Ragoczy and Miller, 2001; Sakakibara et al.,
2001), and through regulation of the activity or abundance of
other transcription factors (Flint and Shenk, 1997; Gruffat
and Sergeant, 1994; Gruffat et al., 1992; Liu et al., 1996;
Manet et al., 1991; Quinlivan et al., 1993).
Rta can transactivate a conserved gammaherpesvirus
gene, gene 57, in KSHV, EBV (referred to as the BMLF1
gene), HVS, and gHV68 (Gruffat et al., 1992; Kenney et al.,
1989; Liu et al., 2000; Wang et al., 2001; Whitehouse et al.,
1998). There are gene 57 homologs in all known herpesvi-
Fig. 1. NIH 3T12 cells were either mock-infected or infected with wt BAC
or G50 KO at an MOI = 1.0 and harvested at 24 h post-infection. Infected
cells were either mock treated or cultured in the absence or presence of PAA
(200 Ag/ml) to inhibit viral DNA replication. Total RNA was isolated and
50 ng of converted RNA was subjected to quantitative RT-PCR using
primers for the gene 57 promoter region. The estimated copy numbers of
viral gene transcripts are indicated with a dashed line (1 copy per cell). The
presence of PAA significantly decreased the level of some viral transcripts
in wt, but not in G50 KO-infected cells. Data are compiled from two
experiments (with the exclusion of ORF 25, 59, and 75c).
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in HCMV (McGeoch et al., 1988; Perera et al., 1994;
Winkler et al., 1994), and in several cases these gene
products have been shown to play a critical role in viral gene
expression during virus replication. The gene 57 product
can activate and repress viral genes at the post-transcrip-
tional level and is involved in nuclear export of viral
transcripts and redistribution of splicing factors (Buisson et
al., 1989; Chevallier-Greco et al., 1989; Cho et al., 1985;
Sandri-Goldin and Mendoza, 1992; Whitehouse et al., 1998;
Wong and Levine, 1986).
Previously, we have shown that gHV68 Rta can trans-
activate the gene 57 promoter in the absence of other viral
proteins (Liu et al., 2000). The studies presented here extend
this analysis and show that gene 57 expression is dependent
on the presence of Rta during viral infection. Additionally,
deletion analyses in the gene 57 promoter have identified
two regions, response elements (RE) RE-A and RE-B, that
are critical for Rta-dependent transactivation. These sequen-
ces are also sufficient to confer Rta responsiveness on a
heterologous promoter. Testing a combination of deletions
and subfragments in these regions for Rta-dependent trans-
activation has identified two sets of elements within RE-A
and RE-B that are critical for Rta transactivation and that
partially overlap with elements homologous to the pre-
viously identified KSHV Rta-responsive cis-elements
(Lukac et al., 2001; Song et al., 2001; Wang et al., 2001).Results
cHV68 Rta is required for gene 57 expression during lytic
infection
Previously, we cloned a 565-bp fragment upstream of the
predicted gene 57 transcriptional start site [based on
previous transcript mapping (Mackett et al., 1997)] and
demonstrated that the gene 57 promoter is Rta responsive in
the absence of other viral factors (Liu et al., 2000). To
analyze the requirement for Rta for gene 57 expression
during lytic viral infection, we employed a Rta null mutant
[G50 KO(BAC) (Pavlova et al., 2003)] to analyze gene 57
expression in the presence or absence of Rta. Murine NIH
3T12 fibroblasts were infected with wt gHV68(BAC) or
G50 KO(BAC) virus at a multiplicity of 1 PFU per cell, and
total RNA was prepared at 12 h post-infection. This RNA
was reverse-transcribed using oligo(T) priming and ana-
lyzed for expression of spliced gene 57 transcripts using a
quantitative real-time PCR assay (see Materials and
methods). As expected, gene 57 expression was severely
affected in cells infected with the G50 KO(BAC) virus, with
N1000-fold reduction the levels of expression compared to
wt gHV68(BAC) virus (Fig. 1).
Notably, previous studies have shown that the G50
KO(BAC) virus, in contrast to wt(BAC) virus, cannot
replicate in NIH 3T12 cells (Pavlova et al., 2003). Toaddress the possibility that transcription of gene 57 is
attenuated due to decreased viral genome templates for
transcription, the experiments were repeated in the presence
of phosphonoacetic acid, at a concentration which inhibits
viral DNA replication (measured by real-time PCR), and
transcription of gene 57 assessed at 24 h post-infection
(Fig. 1). The latter analysis confirmed that expression of the
spliced gene 57 transcript is severely attenuated in infected
cells in the absence of Rta expression, indicating that Rta is
required for efficient gene 57 transcription (Fig. 1).
Notably, low level gene 57 transcription was observed in
cells infected with the Rta null virus in the presence of PAA
(Fig. 1), suggesting that there is some Rta-independent
transcription of gene 57 during the early phase of virus
infection. However, the levels of gene 57 transcript under
these conditions were ca. 10,000-fold lower than in the
presence of Rta. These studies, taken together with the
ability of Rta to transactivate the gene 57 promoter in
murine NIH 3T12 fibroblasts, in the absence of other viral
factors, demonstrate Rta-dependent transcription of gene 57
during virus replication.
Identification of cis-elements required for Rta
transactivation of the gene 57 promoter
To identify the minimal region required for Rta-depend-
ent transactivation of the gene 57 promoter, a series of 5V
deletions in the gene 57 promoter were generated (Fig. 2A)
and tested for responsiveness to Rta activation (Fig. 2B).
Truncation of the gene 57 promoter to 183 bp did not
affect transactivation by Rta, indicating that the sequences
between bp 75,218 and 75,599 in the gHV68 genome are
not essential for Rta-dependent activation of the gene 57
Fig. 2. Deletion analysis at the 5V-end of the gene 57 promoter. (A)
Schematic representation of the deletions. The promoter fragments cloned
upstream of the firefly luciferase gene in the pGL2 vector (Promega) are
depicted as boxes. To the left of each box is noted the distance from the
transcriptional start site (+1) in negative numbers, to the right of each box is
the name of the construct. The gHV68 genome coordinates are noted above
each box. Also indicated are the locations of the RE-A and RE-B response
elements. (B) Transcriptional activation of 5V-end deletions in the gene 57
promoter by Rta. Each construct was transfected into NIH 3T12 cells with
either empty pBK or pBK50 as described in Materials and methods. Fold
activation of each of the promoters was calculated in samples with pBK50
over those with pBK. The data were compiled from six independent ex-
periments. (C) Transcriptional activation of constructs d4 and d5 in reverse
orientation (denoted with an R) by Rta. Transfections were performed as
described above. The data were compiled from 3 independent experiments.
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of sequences between bp 75,599 and 75,681 resulted in
about a 9-fold reduction in Rta-dependent transactivation
(construct d5), and a deletion between bp 75,681 and 75,737nearly completely abrogated transactivation of the gene 57
promoter to background levels (construct d6). These results
indicate that the sequences located between bp 75,599 and
75,737 are critical for Rta transactivation of the gene 57
promoter, with bp 75,599–75,681 (response element A, or
RE-A) exhibiting a weaker effect, and bp 75,681–75,737
(response element B, or RE-B) a much stronger Rta-
dependence. Interestingly, Rta transactivation of the gene
57 d4 promoter fragment was orientation-independent (Fig.
2C, compare activities of d4 and d4R reporter constructs).
However, upon deletion of the sequences from bp 75,599 to
75,680 (gene 57 d5), promoter activity was only partially
orientation-independent, with a 10-fold reduction in the fold
activation of d5R compared to d5 and about 6-fold higher
than transactivation of the promoterless pGL2-Basic con-
struct (Fig. 2C). These results suggest that there are cis-
elements within the region from bp 75,599 to 75,680 that
have enhancer-like properties and/or encode a divergent
promoter. Previous reports from other _-herpesviruses have
also identified Rta-responsive cis-elements that act in an
orientation-independent manner (Kenney et al., 1989; Lukac
et al., 2001).
Since the largest change in Rta activation of the gene 57
promoter was observed upon deletion of RE-B (see Fig.
2B), we initially focused on identifying the sequences
within this region that mediate Rta activation. First, a series
of overlapping 10 bp deletions were generated in the context
of the gene 57 d4 promoter construct to assess whether any
of these deletions could reproduce the effect of deleting the
entire region between d4 and d5, or RE-B (Fig. 3A). Two of
the deletions, d4.5 and d4.8, exhibited the most significant
reduction in Rta transactivation, with fold activation near
that of d5, indicating that these might be critical sequences
for Rta transactivation (Fig. 3B). One of the deletions, d4.7,
was transactivated to higher levels (about 4-fold) compared
to d4, suggesting there might be negative regulatory
sequences present within the deleted sequences. However,
none of the mutations abrogated Rta activation of the gene
57 promoter.
Analysis of deletions within RE-B, within the context of
the gene 57 d4 promoter construct, might be muted by the
presence of Rta-responsive cis-elements within RE-A. To
address this issue, we generated the same series of nested
deletions within RE-B within the context of the gene 57 d5
promoter construct (Fig. 4A). Notably, since the sequences
deleted in d4.3 are located upstream of d5, we could not
analyze their effect within the d5 construct (Fig. 4A). In
addition, it should be noted that deletions in d4.4. and d5.4
are not identical—the deletion in d4.4 covers bp 75,679–
75,688 while d5.4 extends from bp 75,681 to 75,690 (Fig.
4A). All other deletions within d5 correspond precisely to
the deletions introduced in the d4 reporter construct. As
expected, deletions within the gene 57 d5 promoter
fragment had a more pronounced effect on Rta trans-
activation (Fig. 4B). Again, we tested whether any of the
deletions in the context of d5 could reproduce the 19-fold
Fig. 3. Analysis of internal 10 base pair deletions within d4. (A) Schematic
representation of deletions d4.3 through d4.11. The boxes indicate the
promoter sequences analyzed, and the breaks in the boxes represent the
respective deletions. The double-headed arrows delineate RE-A and RE-B.
All other designations are the same as for Fig. 2. (B) Transcriptional
activation of internal deletions in d4 by Rta. Calculations were done as in
Fig. 2. The data were compiled from three independent experiments.
Fig. 4. Analysis of internal deletions within d5. (A) Schematic representa-
tion of deletions d5.4 through d5.11. Designations the same as for Fig. 2.
(B) Transcriptional activation of internal deletions within d4 by Rta.
Calculations were done as in Fig. 2. The data were compiled from six
independent experiments.
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compared to d5 (see Fig. 2B). Deletions 5.5 and 5.6 had the
most severe defect, with Rta transactivation reduced ca. 10-
to 15-fold compared to intact d5. Constructs 5.4, 5.7, and
5.8 had a moderate defect (ca. 3 to 9-fold reduction), while
deletions 5.9, 5.10, and 5.11 had only a minimal impact on
Rta transactivation of the gene 57 promoter (less than 2-fold
reduction in activity).
Gene 57 promoter Rta-responsive elements RE-A and RE-B
confer Rta responsiveness on a heterologous promoter
To determine whether RE-A and RE-B are not only
required, but also sufficient for Rta-dependent trans-activation of the gene 57 promoter, we cloned these
response elements in a single copy upstream of the hsp 70
TATA box (hspTATA-pGL3), which was kindly provided
by David Lukac (Lukac et al., 2001) (Fig. 5A). In
addition, we cloned various fragments within RE-A and
RE-B, as well fragments spanning RE-A and RE-B,
upstream of the hspTATA box (see Fig. 5A). The reporter
constructs containing the complete RE-A response ele-
ment (RE-A/TATA) and the complete RE-B response
element (RE-B/TATA) exhibited the highest levels of
transactivation by Rta, with ca. 45-fold activation of RE-
A/TATA and ca. 6-fold activation of RE-B/TATA (Fig.
5B). These studies indicated that the sequences within
RE-A/TATA and RE-B/TATA are sufficient to mediate Rta
transactivation.
Comparison of these data with the deletion analysis from
Fig. 2B raised the question of whether there are sequences at
the 3V-end of RE-A that can account for the high level of Rta
transactivation of construct RE-A/TATA and the gene 57 d4
Fig. 5. Analysis of response elements (RE) within the gene 57 promoter.
(A) Schematic representation of RE-A/TATA through RE-C4/TATA, each
of which was cloned upstream of the hsp 70 TATA box of hspTATA-pGL3
(kind gift of David Lukac). The black box depicts the elements with
homology to the KSHV Rta RE in the PAN promoter, and the cross-hatched
box depicts three overlapping elements with homology to the KSHV Rta
RE in the 57 promoter. All other designations are the same as for Fig. 2. (B)
Transcriptional activation of gene 57 promoter fragments by Rta. Each
construct was transfected into NIH 3T12 cells with either empty pCMV-
Tag2B or f50pCMV-Tag2B, as described in Materials and methods. Fold
activation of each of the promoters was calculated in samples with f50-
pCMV-Tag2B over those with pCMV-Tag2B. The data were compiled from
six independent experiments.
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element that is homologous to a sequence within the
previously mapped Rta-responsive regions of the KSHV
PAN promoter (PANp RE) (Song et al., 2001). This
sequence has identity in 9 out of 13 base pairs in the left
end of the PANp RE (see Fig. 6 and Discussion). To address
this issue and to further characterize Rta-responsive cis-
elements, several different constructs were generated (Fig.
5A) and tested for Rta activation (Fig. 5B). Transactivationof construct RE-C/TATA, which has a 20 bp 5V-extension of
RE-B/TATA, led to a ca. 3-fold higher activation compared
to RE-B/TATA (Fig. 5B). However, transactivation of d4.5,
which has the same 20 bp 5V-extension of RE-B in the
context of d5, was not higher compared to d5 (Fig. 5B),
suggesting that in the context of sequences downstream of
RE-B the additional upstream sequence does not augment
Rta transactivation. Furthermore, transactivation of con-
structs RE-A1/TATA and RE-A2/TATA (see Fig. 5A) was
very low, with at least a 10-fold reduction in activation
compared to RE-A/TATA (Fig. 5B). It is possible that
critical cis-sequences are located at the junction between
RE-A1/TATA and RE-A2/TATA. Another possibility is that
the Rta-responsive elements within that region cannot
function in isolation in a single copy. Similarly, analysis of
subfragment of RE-C also largely failed to identify a
smaller region that was efficiently transactivated by Rta
(see Fig. 5B). However, Rta transactivation of sub-
fragment RE-C4/TATA, which consists of RE-C1 and
RE-C2, was ca. 43-fold, which was higher than the levels
of Rta activation of RE-C and equal to that observed with
RE-A and d5. As discussed below (see Discussion), this
fragment contains elements homologous to the KSHV
PANp and 57p REs. It is currently unclear why RE-C4/
TATA has a higher transactivation capacity compared to
RE-C/TATA. It is possible that sequences at the 3’-end of
RE-C contain a repressive cis-element(s). Overall, these
analyses identify the presence of several critical cis-
elements involved in mediating Rta-dependent transactiva-
tion of the gene 57 promoter.Discussion
Previously, we have shown that gHV68 Rta can
transactivate the gene 57 promoter in the absence of other
viral factors (Liu et al., 2000). This is consistent with the
findings that Rta from several different _-herpesviruses can
also transactivate gene 57 in the absence of other viral
products, and suggests a conserved function of Rta in the
regulation of gene 57 expression. The studies presented
here extend this analysis and show that gene 57 expression
is dependent on Rta expression during viral infection.
Additionally, we have mapped a minimal Rta-responsive
gene 57 promoter and identified two major regions,
response elements RE-A and RE-B, that are necessary
and sufficient to confer Rta-dependent transactivation of
the gene 57 promoter.
Analysis of a number of deletions and subfragments in
these regions has identified two sets of elements within RE-
A and RE-B that are critical for Rta transactivation and
which have homology to previously identified KSHV Rta
response elements (Lukac et al., 2001; Song et al., 2001;
Wang et al., 2001). One element is located at the 3’-end of
RE-A and contains sequences that are similar to the KSHV
Rta RE in the PAN promoter, with identity in 9 out of 12 bp
Fig. 6. Nucleotide sequence of the gene 57 RE-A and RE-B elements and identification of sequence homology to known Rta RE in KSHV. Sequences with
homology to known Rta RE within the KSHV PAN promoter (Song et al., 2001) or the KSHV 57 promoter (Lukac et al., 2001; Wang et al., 2001) are
underlined and the KSHV Rta RE sequence shown above the gHV68 sequence. Two candidate RBP-Jn/CBF1 binding sites within RE-B are indicated by
arrows beneath the RE-B sequence, and the consensus RBP-Jn/CBF1 binding site is shown above the RE-B sequence.
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mediate Rta transactivation since fragment RE-A2, which
contains this sequence, is not responsive to Rta. The
presence of at least one other critical cis-element in RE-A
is suggested by the following data: (i) the significant
contribution of RE-A (compare d3 and d4, Fig. 2B); (ii)
the lack of Rta activation of fragments RE-A1 and RE-A2
(Fig. 6B); and (iii) the context-dependent contribution of the
KSHV PANp RE-like element (compare d4, d5, d6, RE-C,
RE-C1, RE-C4; see Fig. 5B).
The other element with homology to a KSHV Rta RE is
located within RE-B, which contains two overlapping
elements with homology to the Rta RE present in the
KSHV gene 57 promoter, with identity ranging from 8 to
11 out of 15 bp (Fig. 5). Importantly, deletion in the 5V-end
of the homologous sequences results in Rta unresponsive-
ness in the context of d5 (see d5.5 and 5.6, Fig. 4B),
emphasizing the importance of these sequences. However,
fragment RE-C3, which contains both copies of the KSHV
57p RE-like cis-element, was not activated by Rta (Fig.
5B). The latter strongly argues that additional upstream
sequences are required in conjunction with these cis-
elements for Rta activation. Notably, immediately upstream
of the KSHV 57p RE-like cis-elements in RE-B are 2
candidate binding sites for the cellular transcription factor
RBP-Jn/CBF1 (see Fig. 6). Each of these putative RBP-Jn/
CBF1 closely match the consensus RBP-Jn/CBF1 binding
site (identity at 6 of 7 bp). In the case of KSHV infection,
it has been shown that RBP-Jn/CBF1 can recruit KSHV
Rta to target promoters and, as such, plays an important
role in Rta activation of some KSHV lytic genes (Liang et
al., 2002). RBP-Jn/CBF1 is the target of the Notch
signaling pathway. In the basal state, RBP-Jn/CBF1recruits corepressor complexes (e.g., SMRT and CIR)
and, as such, inhibits transcription of genes containing
RBP-Jn/CBF1 binding sites (Kao et al., 1998; Hsieh et al.,
1999). However, recruitment of Rta to RBP-Jn/CBF1
likely displaces the corepressor complex leading to
activation of gene transcription (Liang et al., 2002).
Notably, there is evidence that recruitment of Rta to
KSHV lytic promoters by RBP-Jn/CBF1 may be facilitated
by adjacent Rta DNA binding sites, which on their own
are insufficient to recruit Rta to the promoter (Liang et al.,
2002). Thus, like KSHV, gHV68 may exploit RBP-Jn/
CBF1 to regulate Rta-dependent lytic gene expression.
Further studies will be required to determine whether Rta
binds directly to cis-elements within the gene 57 promoter
and/or is recruited to the promoter by cellular transcription
factors (e.g., RBP-Jn/CBF1).Materials and methods
Quantitative RT-PCR
NIH 3T12 cells were either mock-infected or infected
with wt gHV68(BAC) or G50 KO(BAC) at an MOI = 1 and
harvested at 24 h post-infection. Total RNA was isolated
using RNeasy mini kit (Qiagen) and was reverse-transcribed
with poly(T) priming using SuperScript First Strand Syn-
thesis System for RT-PCR (Invitrogen). 50 ng of each
sample was used per PCR reaction using the QuantiTect
SYBR Green PCR Kit (Qiagen) in a 30 Al reaction volume
using two sets of gene 57-specific primers. All PCR
reactions were performed in duplicate on a Bio-Rad iCycler
Real-Time PCR instrument and analyzed using iCycler 3.0
I. Pavlova et al. / Virology 333 (2005) 169–179176software. To generate a standard curve, dilutions of the wt
gHV68(BAC) or pDWGAP/50 (for GAPDH) of known
copy number were run in parallel with each primer set.
GAPDH copy numbers per reaction did not vary signifi-
cantly, ranging from 5  105 to 1  107 per 50 ng of
converted RNA. For experiments using the viral DNA
polymerase inhibitor phosphonoacetic acid (PAA), NIH
3T12 cells were either mock-infected or infected with wt
gHV68(BAC) or G50 KO(BAC) at an MOI = 1, and PAA
was added to the media at 200 Ag/ml. Samples were
harvested at 24 h post-infection, processed as described
above, and cDNA corresponding to 50 ng of RNA was
analyzed using quantitative PCR.
Construction of 5V-deletions in the gene 57 promoter
Previous studies in our lab reported the cloning of a 565-
bp fragment upstream of the gene 57 transcriptional start site
(Mackett et al., 1997) that was responsive to Rta expressed
from pBK50 (Liu et al., 2000). This fragment was amplified
from gHV68 genome using the forward primer 21.1 (5V-
GATTGCGTGCTAGCGGATTGCCTGAGAGACTGC)
and the reverse primer 21.2 (5V-CGTCCCAGAAGCTTG-
CACGGTGCAATGTGTCAC). These primers contain NheI
(GCTAGC) and HindIII (AAGCTT) sites (underlined),
respectively, and the PCR fragment was cloned into the
NheI and HindIII sites of pGL2-Basic (Stratagene). The
resultant plasmid will be referred to as 57pLuc. 5V-deletions
within 57pLuc were cloned by PCR amplification of
57pLuc using a forward and reverse primer that contained
NheI and HindIII sites (underlined, see below), respectively,
and the PCR fragments were cloned into the NheI and
HindIII sites of pGL2-Basic. The forward primers used
were as follows: for construct d1 29.9 (5V-GATTGCG
TGCTAGCCAGCTTCGTGCTGACAAACC), for d2,
29 .10 (5 V-CATACGCAGCTAGCATC CTGCAA-
GACTGTGGCC), for d3, 29.11 (5V-CAATTGCCAGC-
TAGCGGATAGACACCACC TTGTG), for d4, 29.12 (5V-
CATACGCTGCTAGCCTGAAACCTCGCAGAGGTC),
for d4.5, 43.1 (5 V-GTGAGGGCTAGCTAATGT-
GAGGCTTTTC), for d5, 29.13 (5V-GATTGCGT GCT-
AGCCCTGGGAAAGTTCTCACG), for d6, 29.14 (5V-
GAACCCCTGCTAGCGCCA ATAAGTGCAACAAC),
and reverse primer 21.2 (5V-CGTCCCAGAAGCTTG-
CACGGTGCA ATGTGTCAC). For constructs that had
regions of the gene 57 promoter in reverse orientation, the
forward primers were as follows: for construct d4L(R),
29.15 (5V-CATACGCTAAGCTT CTGAAACCTC-
GCAGAGGTC), for d5R 29.16 (5 V-CATACGC-
TAAGCTTCCCTGGGAA AGTTCTCACG), and reverse
primer 21.6 (5V-GATACTAAGCTAGCGCACGGTGCAAT
GTGTCAC). Fig. 2A contains a schematic of the 5V-
deletions within the gene 57 promoter that includes the
genome coordinates of the regions used and the position
relative to the transcriptional start site (+1) defined by
Mackett et al. (1997).Construction of internal deletions in G57p.d4 and G57p.d5
To generate internal 10-bp overlapping deletions
within G57p.d4, QuikChange Site-Directed Mutagenesis
Kit (Stratagene) was used on a G57p.d4 template
according to the manufacturer’s protocol. For each
construct, two primers incorporating the mutations were
used, each complimentary to opposite strands of G57p.d4.
The top primer sequences are as follows: for d4.3, 29.23
(5V-CAGAACAAA ATCACATAATGTGAGGC CC-
TGGGAAAGTTCTCACGTGACGTCATAACTGC), for
d4 .4 , 29 .25 (5 V-GAACAAAATCACATAATGT-
GAGGCTTTTCAT AAGTTCTCACGTGAC GTCA-
TAACTGCAAC), for d4.5, 29.27 (5V-CACATAATGTQ
GAGGCTTTTCATAACCCT G CACGTGACGTCA-
TAACTGCAACACTTATGAG), for d4.6, 29.29 (5V-
GTGAGGCTTT TCATAACCCTGGGAAAGT CGTCA-
TAACTGCAACACTTATGAGTCAATGC), for d4.7,
29.31 (5V-CATAACCCTGGGAAAGTTCTCACG ACTG-
CAACACTTATGAGTCAA TGCTTTGCCAATAAG), for
d4.8, 29.33 (5 V-CATAACCCTGGGAAAGTTCT-
CACGTGACG TC CACTTATGAGTCAAGGCTTGCC),
for d4.9, 29.35 (5V-CCCTGGGAAAGTTCTCACGT
GACGTCATAACTG GAGTCAATGCTTTGCCAA-
TAAGTGC), for d4.10, 29.37 (5V-CTC ACGTGACGT-
CATAACTGCAACACT GCTTTGCCAATAAGTGCAA-
CAACAATAAGCC), for d4.11, 29.39 (5V-CGTGACGQ
TCATAACTGCAACACTTATGAGT CAATAAGTGC
AACAACAATAAGCCTGTGAC). The incorporation of
correct deletions was confirmed by sequence analysis.
To generate internal deletions within G57p.d5, the
deletions within G57p.d4 were PCR amplified using the
following forward primers: for d5.4, 29.11F (5V-GTTT-
CAGCTCTAGAGTT CTCACGTGACGTCAT), for d5.5,
29.13F (5V-GCACGTGATCTAGACCCTGCCACGT-
GACG TC), for d5.6, 29.14F (5V-GTCGAAAGTCTA-
GACCCTGGGAAAGTCGTCAT), for d5.7–5.11, 29.12F
(5V-CTAAGTTCTCTAGACCCTGGAAAGTTCTCAC),
and reverse primer 29.9R (5V-GGAATGCCAAGCTTG-
CACGGTGCAATG). The forward and reverse primers
contain XbaI (TCTAGA) and HindIII sites, respectively
(underlined). The PCR fragments were cloned into XbaI and
HindIII of pGL2-Basic. The amplification of the correct
sequences was confirmed by sequence analysis. Figs. 2A
and 3A contain a schematic of the internal deletions within
G57p.d4 and G57p.d5 that includes the genome coordinates
of the deletions.
Construction of G57p response elements
The candidate gene 57 promoter response elements (REs)
were PCR amplified using 57pLuc as template and a
forward primer containing an NheI site and a reverse site
containing a BglII site. The primers used were as follows:
for RE-A, 42.1 (5V-AAATAAGCTAGCCTGAAACCTCG-
CAGAG) and 42.2 (5V-GCCTCAAGATCTT TAT-
I. Pavlova et al. / Virology 333 (2005) 169–179 177GAAAAGCCTCACAT), for RE-A1, 42.1 and 43.14 (5V-
GACGGGAGATCTGAGTCA GACAGGAGAAG), for
RE-A2, 43.15 (5V-CACAGGGCTAGCATCAACACA-
GAACAA) and 42.2, for RE-B, 42.5 (5V-TAAATTGC-
TAGCCCTGGGAAAGTTCT) and 42.6 (5V-GCAGTG
AGATCTAAAGCATTGACTCAT), for RE-C, 43.1 (5V-
GTGAGGGCTAGCTAATGTGAGGC TTTTC) and 42.6,
for RE-C1, 43.1 and 43.3 (5V-CGTACGAGATCTTCACGT-
GAGAACTTT CCC), for RE-C2, 43.4 (5V-AAAGTTGC-
TAGCCCCTGGGAAAGTTCT) and 43.5 (5V-GGCA
GTAGATCTTTGCAGTTATGACGTCACG), for RE-C3,
43.6 (5V-GTCATAGCTAGCCACGT GACGTCATAACTG)
and 43.7 (5V-GACCCGAGATCTTGACTCATAAGT-
GTTGCAG), for RE-D, 43.1 and 43.5. The PCR fragment
was cloned into the NheI and BglII sites of hspTATA-pGL3
(Lukac et al., 2001), kindly provided by David Lukac
(University of Medicine and Dentistry of New Jersey,
Newark, NJ). Fig. 4A contains a schematic of the internal
deletions within G57p.d4L and G57p.d5L that includes the
genome coordinates of the deletions.
Transient transfections and luciferase assays
For transfections using constructs with deletions within
the gene 57 promoter, NIH 3T12 cells were co-transfected
with 1 Ag of either pBK (Stratagene) or pBK50 (Liu et al.,
2000) and 1 Ag of either pGL2-Basic or pGL2-Basic
containing the corresponding construct. Data are presented
as fold activation of luciferase activity in the presence and
absence of Rta expression. For transfections using gene 57
promoter response elements, NIH 3T12 cells were co-
transfected with 1 Ag of either pCMV-Tag2B or fG50-
FLAG (in a pCMV-Tag2B background, see Pavlova et al.,
2003) and 1 Ag of either hspTATA/pGL3-Basic or
hspTATA/pGL3-Basic containing the corresponding con-
struct. Data are represented as fold activation of the gene 57
promoter-based constructs in the presence or absence
pBK50. Transfections were performed using the lipid-based
reagents SuperFect (Stratagene) or LT-1 (Mirus) according
the manufacturer’s protocol. Cell lysates were prepared in
400 Al of 1 Passive Lysis Buffer (Promega) at 48 h post-
transfection, and 20 Al of the lysate was assayed for
luciferase activity using the Luciferase Assay System
(Promega).References
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